Information for investors including share information, share analysis, shareholder news and annual reports.

Q2 2014 results: 23 Jul 2014

View Q2 results details and CEO & CFO videos

stock prices
Investing in GSK

Reasons to invest in GSK - a global healthcare company enabling people to do more, feel better and live longer.

Corporate reporting

Find out how GSK is performing with our Annual Report, Corporate Responsibility Report and financial summary.

Press releases

These press releases are intended for business journalists and analysts/investors.
23 July 2014

Results announcement for the second quarter 2014

GSK delivers Q2 2014 turnover £5.6 billion (-4%) and core EPS 19.1p (-12%) on ex-divestment basis (both CER). Q2 dividend 19p (+6%).

22 July 2014

ViiV Healthcare presents phase III data comparing once-daily maraviroc in combination with darunavir/ritonavir with emtricitabine/tenofovir plus darunavir/ritonavir in treatment-naïve adults with HIV-1

An investigational two drug-regimen of maraviroc dosed once daily, combined with darunavir/ritonavir (DRV/r) showed inferior efficacy compared to emtricitabine/tenofovir (FTC/TDF) with DRV/r.

17 July 2014

Trametinib (Mekinist™) and dabrafenib (Tafinlar™) combination demonstrated overall survival benefit compared to vemurafenib; phase III BRAF V600-mutant metastatic melanoma study stopped early

GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the Independent Data Monitoring Committee (IDMC) recommended COMBI-v (MEK116513), a phase III study of its MEK inhibitor, trametinib (Mekinist™), in combination with its BRAF inhibitor, dabrafenib (Tafinlar™), compared to vemurafenib in patients with BRAF V600E or V600K mutation-positive unresectable or metastatic cutaneous melanoma be stopped early.

UK Map
Investor relations UK
GlaxoSmithKline plc
   Tel: 020 8047 5000
980 Great West Road
    Fax: 020 8047 7807
Middlesex TW8 9GS

Investor downloads

Our product pipeline      
Our product pipeline 0.3MB